Characterisation of pulmonary arterial hypertension patients with cardiovascular comorbidities treated with selexipag: real-world evidence from the EXPOSURE study

Back

ESC Professional Premium Access

Characterisation of pulmonary arterial hypertension patients with cardiovascular comorbidities treated with selexipag: real-world evidence from the EXPOSURE study

Session: Pulmonary hypertension around the real world

Topic: Pulmonary Hypertension

Speaker: Professor S. Soderberg (Umea, SE)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Professor Stefan Soderberg

Umea University, Umea (Sweden)

0 follower

4 more presentations in this session

Pulmonary arterial hypertension associated with congenital heart disease: real-world analysis of clinical characteristics, treatment patterns and outcomes from EXPOSURE

Speaker: Doctor M. Escribano Subias (Madrid, ES)

Incident pulmonary hypertension in 13,448 cases investigated with repeat echocardiography: insight from the national echo database of australia (NEDA)

Speaker: Professor S. Stewart (Sydney, AU)

Concomitant initiation of combination therapy with macitentan and tadalafil in pulmonary arterial hypertension (PAH) patients with comorbidities: Real-world data from OPUS and OrPHeUS

Speaker: Professor R. Channick (Los Angeles, US)

Paediatric pulmonary arterial hypertension following congenital heart defect repair: enhanced risk stratification and outcomes in a national cohort

Speaker: Doctor A. Constantine (Birmingham, GB)

Access the full session

Pulmonary hypertension around the real world

Speakers: Professor S. Soderberg, Doctor M. Escribano Subias, Professor S. Stewart, Professor R. Channick, Doctor A. Constantine

Access

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources